Marie-Charlotte Bourrienne, Véronique Le Cam Duchez, Dorothée Faille, Carine Farkh, Mialitiana Solo Nomenjanahary, Juliette Gay, Stéphane Loyau, Clément Journé, Sébastien Dupont, Véronique Ollivier, Jean-Luc J-L Villeval, Isabelle Plo, Valérie Edmond, Martine Jandrot-Perrus, Sylvie Labrouche-Colomer, Bruno Cassinat, Emmanuelle Verger, Jean-Philippe Desilles, Benoît Ho Ho Tin Noé, Aude Triquenot Bagan, Mikaël Mazighi, Nadine Ajzenberg
Cerebral venous sinus thrombosis (CVST) is an uncommon venous thromboembolic event accounting for <1% of strokes resulting in brain parenchymal injuries. JAK2V617F mutation, the most frequent driving mutation of myeloproliferative neoplasms has been reported to be associated with worse clinical outcomes in patients with CVST. We investigated whether hematopoietic JAK2V617F expression predisposes to specific pathophysiological processes and/or worse prognosis after CVST. Using an in vivo mouse model of CVST, we analyzed clinical, biological and imaging outcomes in mice with hematopoietic-restricted Jak2V617F expression, compared to Jak2WT mice...
February 22, 2024: Blood Advances